LOGIN  |  REGISTER
Viking Therapeutics
Amneal Pharmaceuticals

Azenta to participate in the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022 | Last Trade: US$50.00 0.00 0.00

CHELMSFORD, Mass., Nov. 21, 2022 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the virtual 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, which includes a presentation beginning at 3:30 pm ET. The live webcast can be accessed through the Azenta investor relations website at https://investors.azenta.com/events. A replay of the webcast will be available following the event.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

Azenta is headquartered in Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

INVESTOR CONTACTS:
Sara Silverman
Head of Investor Relations
978.262.2635
This email address is being protected from spambots. You need JavaScript enabled to view it.

Sherry Dinsmore
978.262.2400
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB